5-year survival rates
The SEER database tracks 5-year relative survival rates based on age, sex, and race and is considered the most accurate source of survival information. This database uses terms "Localized," "Regional," and "Distant" to describe various stages of small cell lung cancer. 5-year relative survival rate for "both sexes" and "all races" affected by

"Localized" small cell lung cancer is 28.5%;
"Regional" small cell lung cancer 14.9%; and for
"Distant" small cell lung cancer 2.9%. Survival rates by sex
Women affected by small-cell lung cancer have higher 5-year survival rates than men. Localized: Women – 32.2% | Men – 24.5%
Regional: Women – 17.0% | Men – 12.3%
Distant: Women – 3.6% | Men – 2.2%

Survival rates by race, sex, age
5-year relative survival statistics are more accurate and, in some cases, higher when specific race and age range are combined with sex and stage at diagnosis. For example,

Black / Female | Ages < 50 (at diagnosis) | Distant (ES SCLC) | = 7.0%. White / Female | Ages < 50 (at diagnosis) | Distant (ES SCLC) | = 6.1%National Cancer Institutes SEER maintains publicly accessible database for specific survival rates. Epidemiology
15% of lung cancers in the US are of this type. Small cell lung cancer occurs almost exclusively in smokers – most commonly in heavy smokers and rarely in non-smokers. Recalcitrant Cancer Research Act
In 2013, the US Congress passed the Recalcitrant Cancer Research Act, which mandated increased attention to certain recalcitrant cancers, including small cell lung cancer. That led to the National Cancer Institute supporting small cell–specific research through a consortium.
Insulin glulisine is a rapid-acting modified form of medical insulin that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. It was developed by Sanofi-Aventis and approved for marketing by the FDA in 2004; it is sold under the trade name Apidra. When injected subcutaneously, it appears in the blood earlier than human insulin. When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal. Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.The most common side effects include hypoglycaemia (low blood glucose levels). Medical uses
Insulin glulisine is indicated for the treatment of diabetes mellitus. References
External links
"Insulin glulisine". Drug Information Portal. U.S. National Library of Medicine.